The latest from Strata Oncology

Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium

Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards

Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer

Becker's Healthcare Oncology Virtual Forum

Dr. Nair on the clinical utility of Immunotherapy Response Score 

OncLive

Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid Tumors

Gnomeweb

Strata Oncology Strata Select

Cancer Research Communications

Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

Communications Medicine

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

npj Precision Oncology

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

Cureus

Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib

Journal of Precision Oncology

Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome

IASLC23

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

ASCO 2023

Evaluation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab (pembro) Clinical Benefit in Patients (pts) with Advanced Solid Tumors

ASCO20

PCR-based comprehensive genomic profiling (PCR-CGP): Feasibility from >20,000 tumor tissue specimens (TTS) and predicted impact on actionable biomarker identification versus hybrid capture (H)-CGP and plasma (P)-CGP.

IASLC23

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

AACR 2023

Validation of an Integrative Pan-solid Tumor Predictor of Pembrolizumab Monotherapy Benefit

AACR 2023

Strata PATH™: A Multicohort, Non-randomized, Open-label Phase 2 Trial to Explore Efficacy and Safety of FDA-Approved Cancer Therapies in Novel Biomarker-guided Patient Population